Vir Biotech Q4 net loss $101.6M; CEO Scangos retiring, CFO Horn resigning

Vir Biotechnology, Inc.

2022-FY EPS reported $3.83 revenue$1,615,797,000

Q4 2022 revenue $49.4M vs $812.7M YoY; net loss $0.76/share vs net income $4.01/share.
Full year 2022 revenue $1.6B, net income $515.8M ($3.89/share); cash & investments ~$2.4B.
CEO George Scangos retiring April 3, 2023; succeeded by Marianne De Backer (Bayer exec).
CFO Howard Horn resigning; replaced by Sung Lee, 20-year biotech veteran.
Key pipeline catalysts: HBV data H1 2023, influenza PENINSULA data mid-2023, HDV data H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vir Biotechnology, Inc. reported financial results for the fourth quarter ended December 31, 2022.

Period: the fourth quarter ended December 31, 2022
Result: reported results

Exact text from the filing

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vir Biotechnology, Inc. reported the full year ended December 31, 2022 results: revenue $1.5 billion.

Period: the full year ended December 31, 2022
Revenue: $1.5 billion
Result: reported results

Exact text from the filing

– $1.5 billion of sotrovimab collaboration revenue recognized in 2022 –

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Vir Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-004092

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.